Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy

At least six Indian generic drugmakers launched lower-cost versions of Novo Nordisk’s Ozempic and Wegovy, cutting treatment costs by about 70% with globally unmatched pricing. This represents a material competitive and pricing threat to Novo Nordisk’s diabetes and weight‑loss franchise and could pressure sales/pricing in markets where these generics are adopted.

Analysis

At least six Indian generic drugmakers launched lower-cost versions of Novo Nordisk’s Ozempic and Wegovy, cutting treatment costs by about 70% with globally unmatched pricing. This represents a material competitive and pricing threat to Novo Nordisk’s diabetes and weight‑loss franchise and could pressure sales/pricing in markets where these generics are adopted.